Skip to content

Study · Observational study · n = 402 · 2026

4 results

Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?

Katzman J, Alpert Z, Kennedy M, Rozell J, Schwarzkopf R, Lajam C

Archives of orthopaedic and trauma surgery20 Feb 2026

PMID41718773 (opens in a new tab)DOI10.1007/s00402-025-06167-2 (opens in a new tab)PepBankPUB-41718773
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    After total knee arthroplasty, 90-day emergency department visits were 5.7% in semaglutide users, 7.9% after bariatric surgery and 4.0% in controls.

    In plain wordsAfter knee replacement, 5.7% of semaglutide users had an emergency visit within 90 days, against 7.9% after weight-loss surgery and 4.0% in controls.

    Peptide
    Semaglutide
    Outcome
    Direction not reported90-day emergency department visits
    Study

    n = 402

    Comparator
    Bariatric surgery and BMI > 35 control cohorts
    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    90-day ED visit rate
    5.7%
    semaglutide users
    90-day ED visit rate
    7.9%
    bariatric surgery
    90-day ED visit rate
    4%
    controls

    Source sentences

    Summary
    90-day emergency department (ED) visits (7.9 [BS] vs. 5.7 [SU] vs. 4.0% [C], P < 0.001
    1 context sentence
    Summary · context
    A retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650).
  2. 02HumanObservational studySafety outcome

    In multivariate analysis after total knee arthroplasty, semaglutide use was not a significant predictor of adverse outcomes.

    In plain wordsAfter knee replacement, semaglutide use was not linked to more problems in the statistical analysis.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse outcomes after total knee arthroplasty (multivariate analysis)
    Study

    n = 402

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while SU was not a significant predictor of adverse outcomes.
    1 context sentence
    Summary · context
    A retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650).
  3. 03HumanObservational studyEfficacy outcome

    Before total knee arthroplasty, BMI fell by 0.7 kg/m² in semaglutide users, while it rose by 2.1 kg/m² in controls.

    In plain wordsBefore knee replacement, semaglutide users had a small drop in body mass index while controls had a rise.

    Peptide
    Semaglutide
    Outcome
    DecreasePreoperative BMI change
    Study

    n = 402

    Comparator
    BMI > 35 control group
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI change
    0.7 kg/m2
    semaglutide users, decrease
    BMI change
    2.1 kg/m2
    controls, increase

    Source sentences

    Summary
    The BS group achieved the largest preoperative BMI reduction (–1.8 kg/m²) vs. SU (–0.7 kg/m²) and controls (+ 2.1 kg/m²).
    1 context sentence
    Summary · context
    A retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650).
  4. 04HumanObservational studyEfficacy outcome

    The semaglutide cohort regained 1.7 kg/m² of BMI within three years after total knee arthroplasty.

    In plain wordsAfter knee replacement, people who used semaglutide before surgery regained some body mass index within three years.

    Peptide
    Semaglutide
    Outcome
    IncreaseBMI regain within three years after arthroplasty
    Study

    n = 402

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3 yearsAs given in this study (human).

    Measurements

    BMI regain
    1.7 kg/m2
    within three years post-TKA

    Source sentences

    Summary
    Notably, the SU cohort regained 1.7 kg/m² within three years post-TKA.
    1 context sentence
    Summary · context
    A retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.